stockrow
Monday 9 November 2026
Export AVLN’s income statement to Excel — free account
Avalyn Pharma Inc.
AVLN
29.15
2.48
+9.30%
Follow AVLN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | (93) | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | 0 | (76) | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | 8 | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | (96) | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | (1) | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | (97) | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | 347 | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | (338) | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | 398 | — | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 51 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Avalyn Pharma Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics, Inc. | $1.5B | — (loss-making) | — | — | n/m | −135.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.4B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| AVLN Avalyn Pharma Inc. | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | |
| DRTS Alpha Tau Medical Ltd. | $1.3B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.3B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SGP SpyGlass Pharma, Inc. | $1.2B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| Median of peers | $1.2B | — | — | +113.59% | — | −74.04% | 0.00% | 0.00% |